GRDN Guardian Pharmacy Services, Inc. Insider Trading

Morris David K sells 187,855 shares of GRDN at $29.68, reducing stake -42.5%; stock now at $37.57, +12.0% in 30d.

Morris David K sold 187,855 shares on 2026-03-20 at $29.68, reducing his holdings from 442,327 to 254,472 shares, a -42.5% reduction in his prior stake. The sale occurred at a significant discount to current price—the stock has traded as high as $37.57 in the 52-week range and is at that level today, meaning the insider sold roughly 21% below the current market. His prior two sells at GRDN (May 2025) generated positive 90-day returns of 29.1% and 30.1%, indicating both trades were poorly timed from a hindsight perspective. The company shows solid fundamentals with $377.4M in quarterly revenue and +17.9% annual revenue growth, though net income of $9.8M appears constrained relative to the revenue scale. The timing of this large stake reduction, combined with the historical pattern of post-sale gains at this ticker and the substantial gap between execution and current prices, merits monitoring.

Pharmacy Investors, LLC sells 827,636 shares of GRDN for $24.6M at $29.68; stock now at $37.57 (+12.0% in 30 days).

Pharmacy Investors, LLC reduced its stake in Guardian Pharmacy Services by 44.4%, selling 827,636 shares for $24,566,305.57 on 2026-03-20 at $29.68 per share while the stock has since risen to $37.57. The insider's prior two sales at GRDN (May 2025) were both followed by strong 90-day gains of +29.1% and +30.1%, establishing a pattern of selling ahead of rallies rather than before declines. This current transaction fits that historical pattern: the stock has posted +12.0% returns in the 30 days following the sale and has rallied 21.7% over 90 days, placing the sale price near the 52-week low of $19.67. Fundamentally, GRDN is expanding with +17.9% annual revenue growth and $377.4M in quarterly revenue, providing no obvious distress signal. The sale reduces but does not eliminate the insider's position (1.04M shares remain post-transaction), suggesting continued exposure rather than full exit.

Burke Fred sold 671,432 GRDN shares at $29.68 on 2026-03-20 ($19.9M); retains 840,413 shares. Stock now at $37.57.

Burke Fred executed a substantial open-market sale of 671,432 shares (44.4% of prior holdings) at $29.68 per share, reducing his position from 1,511,845 to 840,413 shares. The sale occurred when GRDN was trading significantly below its 52-week high of $37.57—the current price point—indicating the insider sold during a relative low in the stock's recent range. His prior two sales at GRDN (May 2025) both resulted in positive 90-day returns of +29.1% and +30.1%, meaning the stock subsequently appreciated after he sold; neither was well-timed in the sense of preceding a decline. The company shows solid fundamentals with annual revenue growth of +17.9% and $377.4M in quarterly revenue, though the transaction itself does not carry explicit disclosure of reasoning.

Director BINDLEY WILLIAM E sold 3,570,677 shares of GRDN at $29.68 on 2026-03-20, reducing stake 44.4% to 4,469,316 shares ($106.0M transaction).

Director Bindley sold 3,570,677 shares at $29.68, a substantial 44.4% reduction of his pre-transaction holdings, for a total value of $105,986,620.05. The sale occurred at $29.68, well below the current price of $37.57 and below the 52-week high of $37.57, despite the stock trading up 12.0% over the past 30 days and 21.7% over 90 days. Notably, his prior two sales at this ticker (2025-05-28 and 2025-05-27) both resulted in positive 90-day returns of +29.1% and +30.1% respectively, meaning the stock rose after those sales—a pattern of poorly-timed exits. This current sale's timing against the stock's recent strength and his historical pattern of selling before rallies warrants investor attention to whether fundamental business conditions at the company have changed.

Director Thomas J Salentine Jr sold 3,570,677 shares of GRDN for $105,986,620.05, reducing holdings 44.4%

Director Salentine executed a substantial open-market sale of 3,570,677 shares at $29.68, reducing his holdings from 8,039,993 to 4,469,316 shares—a 44.4% reduction in his position. The transaction occurred when the stock was trading 21% below its 52-week high of $37.57 and subsequently rose 12.0% in the 30 days following the sale, demonstrating poorly timed execution relative to near-term price action. Examining Salentine's same-ticker history at GRDN, two prior sales in May 2025 were followed by 30-day gains of 6.0% and 4.9% respectively, with 90-day gains of 29.1% and 30.1%—a pattern suggesting this sale also preceded further appreciation. The company shows solid fundamentals with $377,427,000 in latest-quarter revenue and 17.9% annual revenue growth, yet the insider chose to divest a significant ownership stake near the lower end of the 52-week range.

Bindley Capital Partners I sold 3,570,677 shares (44.4% of pre-transaction holdings) of GRDN at $29.68 on 2026-03-20; stock now at $37.57.

Bindley Capital Partners I divested 3,570,677 shares (3.57M shares) in a single transaction valued at $105,986,620.05 ($106.0M), reducing its stake from 8,039,993 shares (8.04M shares) to 4,469,316 shares (4.47M shares) and cutting its ownership in half by percentage. The sale occurred at $29.68, which proved poorly timed relative to the stock's current $37.57 price and its 90-day appreciation of +21.7%. Across the same ticker, Bindley's two prior sales in May 2025 were both followed by substantial 90-day gains (29.1% and 30.1%), creating a consistent pattern: the firm has sold three times at GRDN and the stock has risen sharply each time afterward, with a same-ticker timing pattern of 0 of 2 prior sells well-timed at the 90-day mark. The company's fundamentals remain constructive, with annual revenue growth of +17.9% and quarterly revenue of $377,427,000.00 ($377.4M), suggesting the sale was not preceded by deteriorating operational performance.

Cardinal Equity Fund sold 275,728 shares of GRDN at $29.68, reducing stake 44.4%; stock now $37.57, up 12.0% in 30 days

Cardinal Equity Fund divested 275,728 shares at $29.68 on 2026-03-20, reducing its position from 620,851 to 345,123 shares (a 44.4% reduction). Since the transaction, GRDN has appreciated to $37.57, representing a 26.6% gain from the sale price, indicating the sale was poorly timed relative to subsequent price action. The insider's same-ticker history at GRDN shows 2 prior sells (2025-05-28 and 2025-05-27) that also posted positive 90-day returns of 29.1% and 30.1% respectively, establishing a pattern where this insider's exit timing at this ticker has not preceded downturns. Against a backdrop of GRDN's 17.9% annual revenue growth and a current price at the 52-week high, the substantial reduction in holdings by a long-standing investor warrants consideration of whether changing portfolio positioning or other factors drove the divestiture.

Director Ackerman sells 1,103,364 shares for $32,750,601.93 at $29.68; retains 345,123 shares post-sale.

John Ackerman, a Director at Guardian Pharmacy Services, Inc. (GRDN), executed 2 separate sales totaling 1,103,364 shares for $32,750,601.93 at $29.68 on 2026-03-20, reducing his holdings by 76.2% from 1,448,487 to 345,123 shares. The sales occurred at a price $8.69 (or 22.7%) below the current market price of $37.57, and at a level 23% below the stock's 52-week high; the stock has appreciated 12.0% over 30 days and 21.7% over 90 days since the transaction date. His prior 4 sales at GRDN posted average 90-day returns of +29.1% and +30.1% (all upside after the sales), indicating a pattern of poorly-timed sell exits at this ticker. The company shows solid fundamentals with $377.4M quarterly revenue and 17.9% annual growth, but Ackerman's substantial reduction of his equity stake—despite strong recent price momentum and a track record of selling before gains—merits investor attention to understand his reasoning.

Forbes Kendall sold 346.7K shares of GRDN at $29.68 on 2026-03-20; stock now $37.57, up 12.0% in 30 days and 21.7% in 90 days.

Forbes Kendall sold 346,672 shares worth $10,290,091.64 at $29.68, reducing holdings from 799,928 to 453,256 shares (-43.3% vs pre-transaction holdings). The stock has appreciated significantly since the sale: +12.0% over 30 days and +21.7% over 90 days, reaching the $37.57 current price which matches the 52-week high. Kendall's prior trades at GRDN (two sales on 2025-05-28 and 2025-05-27) were both followed by stock gains at the 90-day mark (+29.1% and +30.1%), indicating a pattern of selling before periods of appreciation. Guardian's fundamentals remain healthy with $377,427,000.00 in latest quarterly revenue, $9,818,000.00 net income, and annual revenue growth of +17.9%, providing no obvious operational distress that would justify the sales on fundamental grounds.

Director Cosler buys 3,370 GRDN shares at $29.61; adds 15.6% to position, extending prior buy pattern.

Steven D. Cosler, a Director, purchased 3,370 shares at $29.61 on 2025-12-03, increasing his holdings from 21,614 to 24,984 shares—a 15.6% increase. This represents his third open-market purchase of GRDN stock: his prior buy on 2024-09-27 realized a 90-day return of +61.4%, while his more recent buy on 2024-11-19 saw a 90-day return of -6.9%, indicating mixed timing outcomes at this ticker. The current price of $29.76 is only 5.7% below the 52-week high and within recent uptrend context (30-day change +2.7%, 90-day change +5.5%). His cross-ticker track record shows 2 prior open-market buys averaging +27.2% 90-day returns, though with a 50.00% win rate, establishing a pattern of selective but inconsistent success. The transaction value of $99,785.70 reflects a meaningful but not extraordinary capital deployment relative to the company's $377.4M quarterly revenue and $9.8M net income.